NeuroOne reports Q4 product revenue of $2.7M (+907% YoY); full-year loss narrows 71%

NEUROONE MEDICAL TECHNOLOGIES Corp

Product revenue $2.7M in Q4 FY2025, up 907% YoY; full year product revenue $9.1M, up 163% YoY.
Product gross margin improved to 55.8% in Q4 and 56.5% for FY2025, up from 31.3% in FY2024.
Net loss improved 71% to $3.6M ($0.09/share) for FY2025; Q4 net loss $1.6M ($0.03/share) vs $3.4M ($0.11) YoY.
FDA 510(k) clearance for OneRF Trigeminal Nerve Ablation System; first two trigeminal neuralgia patients treated.
Cash & equivalents $6.6M (up from $1.5M); no debt; funded through fiscal 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.